Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2025 Earnings Call Transcript
Anthony DiMeo: Good morning, and thank you for joining Amneal Pharmaceuticals Second Quarter 2025 Earnings Call. Today, we issued a press release reporting Q2 results.
Amneal Pharmaceuticals Inc. (AMRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 11,710,332 | $94,736,586 | +10% | 1.43% |
| 2. | Citadel Investment Group Ken Griffin | 5,624,682 | $45,503,677 | -25% | 0.01% |
| 3. | Millennium Management Israel Englander | 5,043,027 | $40,798,088 | +142% | 0.02% |
| 4. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 4,367,438 | $35,332,573 | +15% | 1.38% |
| 5. | Blackbarn Capital Jonathan Carter | 3,446,570 | $27,882,751 | +20% | 1.6% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.21 | 50,000 | $210,500.00 | 258,784 | 2021-12-17 | Filing | |
| $4.25 | 50,000 | $212,500.00 | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | $413,000.00 | 462,566 | 2021-12-15 | Filing | |
| $4.25 | 50,000 | $212,500.00 | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | $413,000.00 | 462,566 | 2021-12-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.50 | 6,340 | $60,230.00 | 146,403 | 2025-08-25 | Filing | |
| $9.66 | 114,492 | $1,105,992.72 | 152,743 | 2025-08-22 | Filing | |
| $9.38 | 279,244 | $2,619,308.72 | 152,426 | 2025-08-20 | Filing | |
| $9.29 | 71,694 | $666,037.26 | 267,235 | 2025-08-14 | Filing | |
| $9.43 | 219,159 | $2,066,669.37 | 122,152 | 2025-08-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,551,391 | $141,990,753 | 0% | |
| 2. | 12,328,767 | $99,739,725 | 5.32% | |
| 3. | 12,131,359 | $98,142,697 | 0% | |
| 4. | 5,297,370 | $42,857,101 | 0.01% | |
| 5. | 3,915,336 | $31,675,068 | 0% |
News See All
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best strong buy stocks to buy under $10.
10 Best Strong Buy Stocks to Buy Under $10
He stated that there are a couple of factors behind this, including an improvement in trade, as more trade deals continue to be announced.
13 Best Healthcare Stocks to Buy Under $10
On June 27, Tiffany McGhee, CEO of Pivotal Advisors, appeared on CNBC to talk about the best course of action for investors amid current market dynamics.
Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the best growth stocks to invest in for the next 5 years. Gautam Patel, the director of Amneal Pharmaceuticals, Inc.
15 Best Growth Stocks to Invest in for the Next 5 Years
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.
Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets
On June 1, Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) initiated a nationwide recall of 3 specific lots of its Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2025 Earnings Call Transcript
Tony DiMeo: Good morning and thank you for joining Amneal Pharmaceuticals first quarter 2025 earnings call. Today, we issued a press release reporting Q1 results.
10 Best Pharma Stocks to Buy for Long Term Growth
With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript February 28, 2025Amneal Pharmaceuticals, Inc. misses on earnings expectations.
Billionaire Hedge Funds
